Shares of Seattle, Waltham biotech Juno crash after patient deaths

Seattle cancer drug developer Juno Therapeutics, which has a research office in Waltham, saw its share price plummet on Wednesday after announcing that two patients in a mid-stage cancer trial have died.Juno (Nasdaq: JUNO) said it had halted the trial of a leukemia treatment called JCAR015 after two patients died from brain swelling. News about the failed trial, referred to by Juno as the “Rocket” trial, had sent shares of the company down by nearly 28 percent to $21.58 as of 11:50 a